Trials / Completed
CompletedNCT04076787
Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib
The Effect of Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors (TKI) on Clinical Outcomes Among Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received First-Line Sunitinib in the International mRCC Database Consortium (IMDC) Based on Prognostic Risk Score
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,769 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a retrospective, longitudinal cohort study that assessed clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) who received sunitinib as first-line treatment.
Detailed description
Clear cell mRCC patients who initiated sunitinib as first-line treatment between 2010 and 2018 were identified from the IMDC database. Patients were classified as favorable, intermediate, or poor prognostic risk group according to IMDC criteria. Overall survival, time to treatment discontinuation, and physician-assessed tumor response were evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sunitinib | patients who received sunitinib as first line therapy for mRCC |
Timeline
- Start date
- 2018-09-01
- Primary completion
- 2018-09-02
- Completion
- 2018-09-02
- First posted
- 2019-09-03
- Last updated
- 2023-04-06
- Results posted
- 2019-10-10
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT04076787. Inclusion in this directory is not an endorsement.